Psychopharmacotherapy of Premenstrual Dysphoric Disorder- New Vistas

Affiliations

27 June 2022


Abstract

Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.

Keywords: PMDD; allopregnanolone; psychopharmacology.


Similar articles

Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.

Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T.Psychoneuroendocrinology. 2017 Jun;80:46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1.PMID: 28319848 Clinical Trial.

The pharmacotherapeutic management of premenstrual dysphoric disorder.

Ciccone N, Kovacheff MB, Frey BN.Expert Opin Pharmacother. 2023 Jan;24(1):145-151. doi: 10.1080/14656566.2022.2114345. Epub 2022 Aug 22.PMID: 35974667

Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.

Bixo M, Johansson M, Timby E, Michalski L, Bäckström T.J Neuroendocrinol. 2018 Feb;30(2). doi: 10.1111/jne.12553.PMID: 29072794 Review.

A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.

Bäckström T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, Panay N, O'Brien S.Psychoneuroendocrinology. 2021 Nov;133:105426. doi: 10.1016/j.psyneuen.2021.105426. Epub 2021 Sep 23.PMID: 34597899 Clinical Trial.

Premenstrual Dysphoric Disorder.

Lanza di Scalea T, Pearlstein T.Med Clin North Am. 2019 Jul;103(4):613-628. doi: 10.1016/j.mcna.2019.02.007.PMID: 31078196 Review.


KMEL References